Rationale for Capgemini’s Acquisition of IGATE
The acquisition bolsters Capgemini’s exposure in the financial verticals—where IGATE is particularly strong—as well as manufacturing, retail, and healthcare.
Basics of the IGATE–Capgemini Transaction
The IGATE–Capgemini merger is a friendly cash merger that will require an IGATE shareholder vote. Capgemini warrants that it will have the funds prior to closing.
Tight Spread on the IGATE Merger with Capgemini
The IGATE (IGTE)–Cap Gemini (CAPMF) merger is a cash deal, with a shareholder vote and a deal with the three biggest holders. The companies have 30 days from the date of the merger agreement to consent.
Does Johnson & Johnson Have a Plan for Huge Cash Reserve?
Johnson & Johnson (JNJ) has a huge cash reserve amounting to ~$15 billion in 4Q14. The company might use the cash for merger and acquisition (or M&A).
Pharmaceutical Segment Is Johnson & Johnson’s Savior in 1Q15
Johnson & Johnson’s (JNJ) pharmaceutical segment reported revenue growth of 3.0% in 1Q15 due to strong growth in cardiovascular-metabolism, oncology, and immunology.
Comcast Is Reportedly Throwing In the Towel on Time Warner Cable
The 14-month saga of Time Warner Cable and Comcast appears to be coming to an end as early as today, April 24. Reportedly, the deal can’t meet FCC standards.
Basics of the Informatica Merger
Informatica has a non-solicitation agreement with a fiduciary out. Prior to shareholder approval, it could discuss another merger if approached by another suitor.
Parsing the Pharmacyclics–AbbVie Merger MAC Clause: Part 2
In the MAC (material adverse change) clause of the Pharmacyclics–AbbVie merger agreement, a financial crisis or a recession is not considered a MAC.
The Pharmacyclics–AbbVie Merger: The Basics of AbbVie
A major reason for the Pharmacyclics–AbbVie merger is to diversify AbbVie away from its reliance on a single product, Humira, and boost its pipeline.
Is the Pharmacyclics–AbbVie Merger a Setup?
The Pharmacyclics–AbbVie merger has been structured in such a way to minimize the potential upside in the election.
Could the Pharmacyclics–AbbVie Merger Get Competitive?
Could the Pharmacyclics–AbbVie merger get broken up by an interloper? It’s not out of the question, but it looks like the auction has already happened.
Is Antitrust a Risk in the Pharmacyclics–AbbVie Merger?
In preparation for the Pharmacyclics–AbbVie merger, the companies will have to file under the Hart-Scott-Rodino Antitrust Improvements Act.
Rationale for the Pharmacyclics–AbbVie Merger
The Pharmacyclics–AbbVie merger is not about synergies, or cost-cutting. It’s about where the combined company will be in five years.
The Pharmacyclics–AbbVie Merger: What Are the Details?
In the Pharmacyclics–AbbVie merger, Pharmacyclics (PCYC) shareholders will receive $261.25 per share. The companies expect a second quarter 2015 close.
The Pharmacyclics–AbbVie Merger – Shareholders Could Benefit
The Pharmacyclics–AbbVie merger is a tender. No shareholder votes are required. If you play your cards right, you’ll get at least $261.25 and possibly more.